These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 18549347)

  • 41. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
    Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
    Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
    Chazot PL
    Curr Opin Investig Drugs; 2007 Jul; 8(7):570-9. PubMed ID: 17659477
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
    De Micco R; Satolli S; Siciliano M; De Mase A; Giordano A; Tedeschi G; Tessitore A
    Neurol Sci; 2022 Jan; 43(1):357-364. PubMed ID: 34031800
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
    Drugs R D; 2004; 5(6):355-8. PubMed ID: 15563241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Safinamide from daily clinical practice: first clinical steps].
    Pagonabarraga J; Kulisevsky J
    Rev Neurol; 2017 Nov; 65(10):433-438. PubMed ID: 29130466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safinamide (Newron Pharmaceuticals).
    Chazot PL
    Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor.
    Podurgiel S; Collins-Praino LE; Yohn S; Randall PA; Roach A; Lobianco C; Salamone JD
    Pharmacol Biochem Behav; 2013 Apr; 105():105-11. PubMed ID: 23360954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Safinamide Mesilate (Equfina
    Koebisu M; Ishida T
    Nihon Yakurigaku Zasshi; 2020; 155(4):269-276. PubMed ID: 32612042
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy.
    Bovenzi R; Liguori C; Canesi M; D'Amelio M; De Pandis MF; Marini C; Monge A; Padovani A; Tessitore A; Stefani A; Zappia M;
    Neurol Sci; 2024 Feb; 45(2):573-583. PubMed ID: 37684511
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease.
    Sadeghian M; Mullali G; Pocock JM; Piers T; Roach A; Smith KJ
    Neuropathol Appl Neurobiol; 2016 Aug; 42(5):423-35. PubMed ID: 26300398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of safinamide on dysphagia in Parkinson's disease.
    Hirano M; Samukawa M; Isono C; Nagai Y
    PLoS One; 2023; 18(5):e0286066. PubMed ID: 37228084
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.
    Cattaneo C; Barone P; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2017; 7(1):95-101. PubMed ID: 27802242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improvement of motor function in early Parkinson disease by safinamide.
    Stocchi F; Arnold G; Onofrj M; Kwiecinski H; Szczudlik A; Thomas A; Bonuccelli U; Van Dijk A; Cattaneo C; Sala P; Fariello RG;
    Neurology; 2004 Aug; 63(4):746-8. PubMed ID: 15326260
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study.
    Rinaldi D; Sforza M; Assogna F; Savini C; Salvetti M; Caltagirone C; Spalletta G; Pontieri FE
    J Neural Transm (Vienna); 2021 Feb; 128(2):273-277. PubMed ID: 33068177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies.
    Wasan H; Singh D; Kh R
    Brain Res Bull; 2021 Mar; 168():165-177. PubMed ID: 33387637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
    Morsali D; Bechtold D; Lee W; Chauhdry S; Palchaudhuri U; Hassoon P; Snell DM; Malpass K; Piers T; Pocock J; Roach A; Smith KJ
    Brain; 2013 Apr; 136(Pt 4):1067-82. PubMed ID: 23518709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
    Gonzalez-Latapi P; Bhowmick SS; Saranza G; Fox SH
    CNS Drugs; 2020 Oct; 34(10):1025-1044. PubMed ID: 32785890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.
    Leuratti C; Sardina M; Ventura P; Assandri A; Müller M; Brunner M
    Pharmacology; 2013; 92(3-4):207-16. PubMed ID: 24136086
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real world data of a German Parkinson's disease population: effectiveness and safety of safinamide in routine clinical practice.
    Jost WH; Gluth I; Lück JC; Lopes OIFDC;
    Curr Med Res Opin; 2023 Dec; 39(12):1621-1628. PubMed ID: 37421634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.